CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at Needham ...

A CRISPR-based system that erases itself from fly populations may offer a safer approach to tackling insecticide resistance ...

Fintel reports that on February 13, 2025, UBS initiated coverage of Jasper Therapeutics (NasdaqCM:JSPR) with a Buy ...

Using a new technology and computational method, researchers from Fred Hutch Cancer Center and The University of Texas MD Anderson Cancer Center have uncovered a biomarker capable of accurately ...

Ocugen (OCGN) is climbing 5% after investment bank H.C. Wainwright raised its price target on the shares to $8 from $7. OCGN, ...

Real-world data highlight gaps in genetic testing and targeted therapy use for metastatic castration-resistant prostate ...

TOKYO -- Japanese researchers from Keio University and elsewhere announced Thursday that they have begun a clinical trial on a gene therapy to restore light sensitivity in patients with retinitis ...

Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient ...

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

State of Alaska Department of Revenue reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.3% ...

From Theresa Caputo to Amy and Joey and our unmistakable accent, Long Island has been the source of innumerable "SNL" gags ...